1. Is Pfizer’s established drugs’ decline in China a canary in a coalmine? — Amgen biosimilar debut boosted by UnitedHealthcare coverage — Novartis CEO says FDA process could’ve been handled better — See more on our front page news

    TRY TWO WEEKS OF OUR EMAIL NEWS HEADLINES FOR FREE
    Dismiss Notice
  2. What happened a year ago this week in biopharma? Regeneron’s Eylea approval, Novartis’ new ethics czar, Vertex’s Kalydeco, and Opidvo’s SCLC approval click to review and read a current update of the big stories from one year ago
    Dismiss Notice

Kimberly-Clark

Anonymous board for Kimberly-Clark

Sort By:
Title
Replies ↓ Views
Last Message
  1. Anonymous
    Replies:
    298
    Views:
    41,748
  2. Anonymous
    Replies:
    171
    Views:
    47,593
  3. Anonymous
    Replies:
    67
    Views:
    21,636
  4. Anonymous
    Replies:
    64
    Views:
    34,581
  5. Anonymous
    Replies:
    64
    Views:
    9,887
  6. Anonymous
    Replies:
    52
    Views:
    9,237
  7. Anonymous
    Replies:
    48
    Views:
    6,218
  8. Anonymous
    Replies:
    43
    Views:
    10,263
  9. Anonymous
    Replies:
    39
    Views:
    7,565
  10. Anonymous
    Replies:
    36
    Views:
    21,266
  11. Anonymous
    Replies:
    33
    Views:
    11,728
  12. Anonymous
    Replies:
    29
    Views:
    6,296
  13. Anonymous
    Replies:
    29
    Views:
    10,754
  14. Anonymous
    Replies:
    26
    Views:
    7,027
  15. Anonymous
    Replies:
    26
    Views:
    4,520
  16. Anonymous
    Replies:
    25
    Views:
    14,026
  17. Anonymous
    Replies:
    23
    Views:
    6,541
  18. Anonymous
    Replies:
    23
    Views:
    2,962
  19. Anonymous
    Replies:
    22
    Views:
    3,370
  20. Anonymous
    Replies:
    21
    Views:
    7,080

Thread Display Options

Loading...